-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
news
newsOn August 17, Pfizer/Bio-Entech submitted to the FDA the early data of the third injection of the new crown vaccine market application
Drug source analysis
Drug source analysisThe main reason for facilitating the submission of this application is the emergence of the delta strain
One reason is that although the existing vaccination has limited protection against delta infection after a period of time, the protection against severe illness and death is still very effective, which is still more than 80%
Pfizer/Bio-Entai's Phase I data show that the third injection increased the delta neutralizing antibody titer by about 100 times, but whether this can be translated into clinical benefits remains to be proven
The new crown is a global pandemic and may also require a global strategy